Navigation Links
Optimer Pharmaceuticals to Present at the Canaccord Genuity Annual Growth Conference
Date:8/1/2011

SAN DIEGO, Aug. 1, 2011 /PRNewswire/ -- Optimer Pharmaceuticals, Inc. (Nasdaq: OPTR) today announced that the Company will present at the Canaccord Genuity Annual Growth Conference on August 10, 2011 at 11:30 a.m. Eastern Time at the InterContinental Hotel in Boston.

(Logo:  http://photos.prnewswire.com/prnh/20090413/LA97352LOGO)

A live audio webcast of this presentation will be accessible in the Investors section of the Company's website at www.optimerpharma.com. Replays of this presentation will be available at the same location for 30 days following the meeting.

About Optimer Pharmaceuticals

Optimer Pharmaceuticals, Inc. is a biopharmaceutical company focused on discovering, developing and commercializing innovative hospital specialty products that have a positive impact on society. Optimer developed and is commercializing DIFICID™ (fidaxomicin) Tablets, an FDA approved antibacterial drug for the treatment of adult patients with Clostridium difficile-associated diarrhea (CDAD). Optimer has filed a marketing authorization application with the European Medicines Agency for fidaxomicin. Optimer's clinical pipeline includes Pruvel™, a product in the fluoroquinolone class of antibiotics that has completed Phase 3 trials as a treatment for infectious diarrhea. Additional information can be found at http://www.optimerpharma.com.

Contacts:
Optimer Pharmaceuticals, Inc.
David Walsey, Vice President, Investor Relations and Corporate Communications
858-909-0736

Canale Communications, Inc.
Jason I. Spark, Senior Vice President
619-849-6005


'/>"/>
SOURCE Optimer Pharmaceuticals, Inc.
Copyright©2010 PR Newswire.
All rights reserved

Page: 1

Related biology technology :

1. Optimer Pharmaceuticals and Clinical Investigators to Present Data at Upcoming Medical Meetings
2. Optimer Pharmaceuticals Reports Inducement Grants Under NASDAQ Listing Rule 5635(c)(4)
3. Optimer Pharmaceuticals, Inc. Announces Exercise in Full of Underwriters Option to Purchase Additional Shares and Closing of Public Offering of Common Stock
4. Optimer Pharmaceuticals to Present at the 29th Annual J.P. Morgan Healthcare Conference
5. Optimer Pharmaceuticals to Present at Oppenheimer Healthcare Conference
6. Optimer Pharmaceuticals Announces Presentations at Upcoming IDSA Annual Meeting
7. Optimer Announces Presentation of Additional Data from Fidaxomicin Phase 3 Study for the Treatment of Clostridium difficile Infection (CDI) Presented at ICAAC
8. Optimer Pharmaceuticals Phase 3 Clinical Trials show Fidaxomicin is Superior to Vancomycin in Treatment of Recurrent Clostridium difficile Infection (CDI); Data Presented at ICAAC
9. Optimer Pharmaceuticals Reports Third Quarter 2009 Financial Results
10. Optimer Pharmaceuticals to Present at September 2009 Investor Conferences
11. Optimer Pharmaceuticals Announces Presentations of Additional Phase 3 Fidaxomicin and Prulifloxacin Data at Upcoming ICAAC Annual Meeting
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:11/24/2014)... , Nov. 24, 2014  Last week, Representatives ... Butterfield (D-NC) took a bold bipartisan step ... introducing the OPEN Act. Original co-sponsors of the ... The Act will incentivize drug makers and innovators ... diseases and pediatric cancers, which opens the door ...
(Date:11/24/2014)... BELLINGHAM, Washington, USA (PRWEB) November 23, 2014 ... the dynamic field of optics and photonics is now available ... no or very low cost. SPIE, the international society ... making access to the complete SPIE Digital Library ... a subsidized price. , “Light-based technologies are integral to all ...
(Date:11/24/2014)... 24, 2014  Spherix Incorporated (Nasdaq: ... the fostering and monetization of intellectual property, today ... Ltd.,  Case No. 3:13-cv-03494-M and  Spherix v. Uniden ... in the United States District Court for the ... On November 21, 2014 the ...
(Date:11/22/2014)... 21, 2014 During his lifetime Richard ... need to surround himself with great people and take ... his friends often marveled at his extraordinarily courageous attitude ... life and -- even with his death impending—that’s how ... disease that would ultimately take his life. , Carrying ...
Breaking Biology Technology:OPEN Act Introduced to Repurpose Drugs for Rare Diseases 2SPIE Digital Library Now Available to High Schools, Two-Year Colleges at No or Low Cost 2Markman Hearing Held as Scheduled in VTech and Uniden Cases 2Sherry Sharp, Wife of CarMax Founder, Richard Sharp, Accepts Seat on Board of Cure Alzheimer’s Fund 2Sherry Sharp, Wife of CarMax Founder, Richard Sharp, Accepts Seat on Board of Cure Alzheimer’s Fund 3
... Neurognostics, Inc ., a Wisconsin company specializing ... announced today that the Food and Drug Administration (FDA) ... its trademarked MindState fDAD. MindState fDAD had previously ... acquisition device. The Special 510(k) allows Neurognostics to enhance ...
... Merge eMed , a Merge Healthcare ... company, today announced the release of Cedara I-ReadMammo ... mammography workstation software product is designed to help ... in adopting digital mammography. , ,I-ReadMammo was ...
... happen. In a country that invented take out food, that is ... is perpetually in motion, it was inevitable that work and indeed ... ten years, the place where knowledge work happens has shifted from ... deck, in a subway car, walking down the street or of ...
Cached Biology Technology:Who moved the workplace? 2Who moved the workplace? 3Who moved the workplace? 4
(Date:11/4/2014)... In nature, the right amount of death at the ... density, according to new research that could help in ... wildlife stocks. , In a paper in the journal ... University researcher and European colleagues conclude that the kind ... a loss of individuals, or mortality, depends on the ...
(Date:11/4/2014)... examining only marketing directed at children on the ... found that the majority of black, middle-income and ... tactics. , Authored by Arizona State University researcher ... the first to examine the use of child-directed ... food restaurants and its relationship to demographics. It ...
(Date:11/4/2014)... , Nov. 4, 2014   Neurotechnology ... today announced that the latest version of its ... the Ongoing MINEX evaluation organized by ... fingerprint algorithms using the INCITS 378 fingerprint standard ... requirement in public tenders in the ...
Breaking Biology News(10 mins):When less is more: Death in moderation boosts population density in nature 2Fast food marketing for children disproportionately affects certain communities 2Fast food marketing for children disproportionately affects certain communities 3Neurotechnology Places Second in Ongoing MINEX Ranking for Fingerprint Matching Algorithms 2Neurotechnology Places Second in Ongoing MINEX Ranking for Fingerprint Matching Algorithms 3
... technology that uses "green" chemistry to help microbes break ... has earned kudos from the editors of Environmental Protection ... the Year. , The technology, which was invented by ... and licensed and manufactured by EOS Remediation, LLC, a ...
... , This release is available in French ... has played a role in the development of the many ... dart frog, according to a study that will be published ... University of Montreal biologist Mathieu Chouteau. The researcher,s methodology was ...
... James Wilkinson at the University of Southampton,s Optoelectronics ... Council (ERC) Advanced Grant to realise tools for ... analysis in water pollution and food safety. , ... biophotonics research in near- to mid-infra-red devices. ...
Cached Biology News:Predators drive the evolution of poison dart frogs' skin patterns 2
More cell-permeant than acridine orange....
Anti-rat Ig HRP detection kit...
One bottle containing 30 ml of protein solution and 0.1% sodium azide....
Used in May-Grunwald Giemsa stain....
Biology Products: